Silexion Therapeutics Ltd. (SLXNW) Research

Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer. Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

Market snapshot

Symbol
SLXNW
Price
$0.04
Day change
+75.40%
Market cap
$1.1M
P/E ratio
-0.07x
52-week range
0.032-0.049
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Aclarion, Inc. (ACON)
  • Akari Therapeutics, Plc (AKTX)
  • Dermata Therapeutics, Inc. (DRMA)
  • FOXO Technologies Inc. (FOXO)
  • P3 Health Partners Inc. (PIII)
  • Purple Biotech Ltd. (PPBT)
  • Revelation Biosciences, Inc. (REVB)
  • Syros Pharmaceuticals, Inc. (SYRS)

Recent insider activity

  • Shirvan Mitchell — A-Award (6000 shares) on 2026-06-04
  • Horenshtein Hadar Mirit — A-Award (7500 shares) on 2026-06-04
  • Hadar Ilan — A-Award (10000 shares) on 2026-06-04
  • Shirvan Mitchell — S-Sale (22818 shares) on 2026-03-26
  • Noy Shlomo — A-Award (9091 shares) on 2026-02-20

Open Silexion Therapeutics Ltd. (SLXNW) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.